These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

330 related items for PubMed ID: 20573060

  • 1. Impact of whole-body ¹⁸F-fluorodeoxyglucose positron emission tomography on therapeutic management of non-small cell lung cancer.
    Heo EY, Yang SC, Yoo CG, Han SK, Shim YS, Kim YW.
    Respirology; 2010 Nov; 15(8):1174-8. PubMed ID: 20573060
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R, Higashiyama M, Maeda J, Okami J, Hosoki T, Hasegawa Y, Takami M, Kodama K.
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. 18F-FDG PET/Contrast-Enhanced CT for Initial Staging and Strategic Treatment of Non-Small Cell Lung Cancer: A Prospective Study.
    Promteangtrong C, Kunawudhi A, Phadungrerk R, Iamsa-art C, Chotipanich C.
    J Med Assoc Thai; 2015 Oct; 98(10):1010-8. PubMed ID: 26638593
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study.
    Kalff V, Hicks RJ, MacManus MP, Binns DS, McKenzie AF, Ware RE, Hogg A, Ball DL.
    J Clin Oncol; 2001 Jan 01; 19(1):111-8. PubMed ID: 11134203
    [Abstract] [Full Text] [Related]

  • 8. Limitations of 18F-2-deoxy-D-glucose positron emission tomography in N1 detection in patients with pathologic stage II-N1 and implications for management.
    Kim MP, Correa AM, Hofstetter W, Mehran R, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Erasmus JJ, Swisher SG.
    Ann Thorac Surg; 2015 Feb 01; 99(2):414-20. PubMed ID: 25497068
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Value of 18F-fluorodeoxyglucose positron emission tomography imaging in staging of non-small cell lung cancer].
    Guan Y, He S, Dong J.
    Zhonghua Yi Xue Za Zhi; 2001 Oct 01; 81(19):1180-3. PubMed ID: 11769705
    [Abstract] [Full Text] [Related]

  • 11. Impact of staging with 18F-FDG-PET on outcome of patients with stage III non-small cell lung cancer: PET identifies potential survivors.
    Eschmann SM, Friedel G, Paulsen F, Reimold M, Hehr T, Scheiderbauer J, Budach W, Kotzerke J, Bares R.
    Eur J Nucl Med Mol Imaging; 2007 Jan 01; 34(1):54-9. PubMed ID: 16896660
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The management impact of clinically significant incidental lesions detected on staging FDG PET-CT in patients with non-small cell lung cancer (NSCLC): an analysis of 649 cases.
    Lin M, Ambati C.
    Lung Cancer; 2012 Jun 01; 76(3):344-9. PubMed ID: 22206598
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
    Mertens LS, Fioole-Bruining A, Vegt E, Vogel WV, van Rhijn BW, Horenblas S.
    BJU Int; 2013 Oct 01; 112(6):729-34. PubMed ID: 23790129
    [Abstract] [Full Text] [Related]

  • 17. Focal uptake of fluorodeoxyglucose by the thyroid in patients undergoing initial disease staging with combined PET/CT for non-small cell lung cancer.
    Yi JG, Marom EM, Munden RF, Truong MT, Macapinlac HA, Gladish GW, Sabloff BS, Podoloff DA.
    Radiology; 2005 Jul 01; 236(1):271-5. PubMed ID: 15987980
    [Abstract] [Full Text] [Related]

  • 18. Diagnostic and prognostic values of FDG-PET in patients with non-small cell lung cancer.
    Abe K, Baba S, Kaneko K, Isoda T, Yabuuchi H, Sasaki M, Sakai S, Yoshino I, Honda H.
    Clin Imaging; 2009 Jul 01; 33(2):90-5. PubMed ID: 19237050
    [Abstract] [Full Text] [Related]

  • 19. Clinical stage I non-small cell lung cancer including FDG-PET Imaging: sites and time to recurrence.
    Gauger J, Patz EF, Coleman RE, Herndon JE.
    J Thorac Oncol; 2007 Jun 01; 2(6):499-505. PubMed ID: 17545844
    [Abstract] [Full Text] [Related]

  • 20. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging.
    Shim SS, Lee KS, Kim BT, Chung MJ, Lee EJ, Han J, Choi JY, Kwon OJ, Shim YM, Kim S.
    Radiology; 2005 Sep 01; 236(3):1011-9. PubMed ID: 16014441
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.